Compare Eli Lilly And Co (LLY) vs ProShares UltraPro S&P500 (UPRO) Price & Performance

Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.

Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.

UPRO trades at $138.50, down 0.4% on the day, with technical indicators showing a bearish bias as the stock faces resistance near $140-141 levels. The overall technical signal is bearish with moving averages indicating selling pressure, though oscillators remain neutral. Recent news highlights broader S&P 500 concerns about valuation levels and market concentration in tech stocks, creating headwinds for leveraged ETFs like UPRO.

The outlook for UPRO remains challenged by elevated market valuations and technical resistance. Investment opportunity exists if the S&P 500 breaks through current resistance levels, but risks include continued market volatility and potential mean reversion in tech-heavy indices. The bearish technical setup suggests caution in the near term.